Kathleen Moore to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Kathleen Moore has written about Dose-Response Relationship, Drug.
Connection Strength
0.690
-
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2021 12; 163(3):473-480.
Score: 0.173
-
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645.
Score: 0.157
-
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2020 01; 156(1):13-22.
Score: 0.151
-
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 08; 154(2):294-301.
Score: 0.147
-
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clin Cancer Res. 2020 03 01; 26(5):1025-1033.
Score: 0.038
-
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014 Feb; 32(1):87-93.
Score: 0.024